MITOMYCIN-C THERAPY FOR CORNEAL INTRAEPITHELIAL NEOPLASIA

We treated three patients who had intraepithelial neoplasia involving the visual axis and a subsequent decrease of visual acuity with topica l mitomycin C 0.02% four times daily for ten to 22 days. In two of the three cases, the intraepithelial neoplasia was histologically confirm ed. The intraepithelial neoplastic lesion was replaced by biomicroscop ically normal epithelium within nine weeks of the beginning of drug ad ministration and did not recur during the four to 12 months of followu p. Adverse reactions to topical mitomycin in two patients ranged from minimal conjunctival hyperemia after 14 days to marked hyperemia, ocul ar pain, and blepharospasm after 22 days. These signs and the symptoms , however, disappeared after the drug was discontinued. Administration of topical mitomycin C 0.02% for two weeks may be an effective treatm ent for corneal intraepithelial neoplasia that affects the visual axis .